Auvelity Can Worsen Anxiety in Some Patients
Anxiety is a documented adverse effect of Auvelity, occurring in 4% of patients in clinical trials—significantly more than placebo (1%)—and was the most common reason for treatment discontinuation (2% of patients). 1
Evidence from Clinical Trials
The FDA label for Auvelity clearly identifies anxiety as a notable adverse reaction. In the pivotal 6-week placebo-controlled trial:
- Anxiety occurred in 4% of Auvelity-treated patients vs. 1% with placebo 1
- 2% of patients discontinued Auvelity specifically due to anxiety, making it the leading cause of treatment discontinuation 1
- Other activating side effects were common: insomnia (4%), nervousness/restlessness (documented with dextromethorphan component) 1
Understanding the Mechanism
The anxiety risk stems primarily from the bupropion component, which is a norepinephrine-dopamine reuptake inhibitor with known activating properties. Historical guideline evidence consistently describes bupropion as "activating" and specifically warns it "should not be used in agitated patients" 2. The 2022 AGA guidelines note that the second dose should not be taken late in the day specifically "to minimize the risk of insomnia" 3, reflecting its stimulating nature.
Clinical Context and Risk Factors
Patients at higher risk for anxiety worsening include:
- Those with pre-existing anxiety disorders or agitation
- Patients with history of panic attacks
- Individuals sensitive to stimulant-like effects
- Those taking higher doses or escalating too rapidly
The FDA label explicitly warns about "unusual thoughts or behaviors" and notes that postmarketing reports of bupropion include "nervousness or restlessness, agitation, anxiety, and panic" 1.
Comparative Perspective
Recent systematic reviews provide nuanced context. While bupropion monotherapy may reduce anxiety symptoms in some depressed patients with mild-to-moderate comorbid anxiety 4, 5, SSRIs showed modest advantage over bupropion in patients with high baseline anxiety 4. The 2022 obesity guidelines note that naltrexone-bupropion trials found "no significant difference between groups" for anxiety as a comorbidity, but anxiety still occurred in 0.6-5.4% of treated patients 3.
Practical Management Algorithm
Before prescribing:
- Screen for current anxiety symptoms, panic disorder, or high baseline agitation
- Consider alternative agents (SSRIs/SNRIs) if severe anxiety is prominent
- Discuss the 4% risk of treatment-emergent anxiety
During treatment:
- Start with once-daily dosing for 3 days before advancing to twice daily 1
- Monitor closely within first 1-2 weeks for emerging anxiety, agitation, or insomnia 6
- Avoid late-day dosing of second dose 3
- If anxiety emerges: reduce dose, slow titration, or discontinue if moderate-to-severe
Key caveat: The combination showed faster antidepressant effects (within 2 weeks) 7, 8, which may offset anxiety risk in some patients. However, the 2% discontinuation rate specifically for anxiety cannot be ignored in clinical decision-making.
Bottom line: Auvelity carries a real, documented risk of worsening or causing anxiety that exceeds placebo, driven by its bupropion component's activating properties. This risk is manageable but requires careful patient selection, dose titration, and monitoring—particularly avoiding use in patients with prominent baseline agitation or severe anxiety disorders.